Determinants of summiting success and acute mountain sickness on Mt kilimanjaro (5895 m)

Wilderness and Environmental Medicine

Volumn 20, Issue 4, 2009, Pages 311-317

  Davies, Andrew J ^a,b   Kalson, Nicholas S ^a   Stokes, Suzy ^a,c   Earl, Mark D ^a   Whitehead, Adam G ^a   Frost, Hannah ^a   Tyrell Marsh, Ian ^a,d   Naylor, Jon ^e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^d NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^e PETERBOROUGH DISTRICT HOSPITAL   (United Kingdom)

Author keywords

Acclimatization; Acetazolamide; Altitude

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR;

ACCLIMATIZATION; ACUTE DISEASE; ALTITUDE DISEASE; ARTICLE; HUMAN; KENYA; PHYSIOLOGY; RISK FACTOR; TIME;

ACCLIMATIZATION; ACETAZOLAMIDE; ACUTE DISEASE; ALTITUDE SICKNESS; CARBONIC ANHYDRASE INHIBITORS; HUMANS; KENYA; RISK FACTORS; TIME FACTORS;

EID: 75449090442     PISSN: 10806032     EISSN: None     Source Type: Journal    
DOI: 10.1580/1080-6032-020.004.0311     Document Type: Article

References (24)

1. Fitzpatrick M, Fletcher M, Wenk D, eds. Trekking in East Africa. 3rd ed. Melbourne, Australia: Lonely Planet Publications Pty Ltd; 2003.
2. Hauser M, Mueller A, Swai B, Moshi E, Ole Nguyaine S. Deaths due to high altitude illness among tourists climbing Mt Kilimanjaro. Proceedings of the 2004 South African Travel Medicine Society, Cape Town, South Africa, Feb 9- 11, 2004. Available at: http://www.sastm.org.za/articles/ AECTM-Abstracts.pdf. Accessed May 5, 2008.
3. Ward MP, Milledge JS, West JB. High Altitude Medicine and Physiology. 3rd ed. London, UK: Arnold Publishers Ltd; 2000.
4. Pollard AJ, Murdoch DR. The High Altitude Medicine Handbook. 3rd ed. Abingdon, UK: Radcliffe Medical Press Ltd; 2003.
5. Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001;345:107-114.
6. Basnyat B, Murdoch DR. High-altitude illness. Lancet. 2003;361:1967-1974.
7. Schoene RB. Unraveling the mechanism of high altitude pulmonary edema. High Alt Med Biol. 2004;5:125-135.
8. Expedition Advisory Centre of the Royal Geographical Society. Guidance for those trekking on Mt Kilimanjaro. Available at: http://www.rgs.org/NR/ rdonlyres/AF725A7E- 276D-4007-94A5-66AD67C3D83B/0/kilimanjaro.pdf. Accessed March 9, 2008.
9. Burtscher M, Szubski C, Faulhaber M. Prediction of the susceptibility to AMS in simulated altitude. Sleep Breath. 2008;12:103-108.
10. Roach RC, Greene ER, Schoene RB, Hackett PH. Arterial oxygen saturation for prediction of acute mountain sickness. Aviat Space Environ Med. 1998;69:1182-1185.
11. Leaf DE, Goldfarb DS. Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. J Appl Physiol. 2007;102:1313-1322.
12. Ried LD, Carter KA, Ellsworth A. Acetazolamide or dexamethasone for prevention of acute mountain sickness: a meta-analysis. J Wilderness Med. 1994;5:34-48.
13. Swenson ER, Duncan TB, Goldberg SV, Ramirez G, Ahmad S, Schoene RB. Diuretic effect of acute hypoxia in humans: relationship to hypoxic ventilatory responsiveness and renal hormones. J Appl Physiol. 1995;78:377-383.
14. Roach R, Bartsch P, Hackett PH, Oelz O. The Lake Louise AMS Scoring Consensus Committee. The Lake Louise acute mountain sickness scoring system. In: Sutton JR, Coates G, Hutton CS, eds. Hypoxia and Molecular Medicine: Proceedings of the 8th International Hypoxia Symposium. February 9-13, 1993; Lake Louise, Canada. Burlington, VT: Queen City Printers; 1993.
15. Maggiorini M, Muller A, Hofstetter D, Bartsch P, Oelz O. Assessment of acute mountain sickness by different score protocols in the Swiss Alps. Aviat Space Environ Med. 1998;69:1186-1192.
16. Kalson NS, Davies AJ, Stokes S, et al.. Climbers with diabetes do well on Mount Kilimanjaro. Diabet Med. 2007; 24:1496.
17. Stokes S, Kalson N, Earl M, et al.. Bronchial asthma on Mount Kilimanjaro is not a disadvantage. Thorax. 2008;63: 936-937.
18. Karinen H, Peltonen J, Tikkanen H. Prevalence of acute mountain sickness among Finnish trekkers on Mount Kilimanjaro, Tanzania: an observational study. High Alt Med Biol. 2008;9:301-306.
19. Ziaee V, Yunesian M, Ahmadinejad Z, et al.. Acute mountain sickness in Iranian trekkers around Mount Damavand (5671 m) in Iran. Wilderness Environ Med. 2003;14:214-219.
20. Basnyat B, Subedi D, Sleggs J, et al.. Disoriented and ataxic pilgrims: an epidemiological study of acute mountain sickness and high-altitude cerebral edema at a sacred lake at 4300 m in the Nepal Himalayas. Wilderness Environ Med. 2000;11:89-93.
21. Imray CH, Kennedy CH, Pattison K, Brearey S, Wright A; Birmingham Medical Research Expeditionary Society. Self-assessment of acute mountain sickness in adolescents: a pilot study. Wilderness Environ Med. 2004;15:202-206.
22. Basnyat B, Gertsch JH, Johnson EW, Castro-Marin F, Inoue Y, Yeh C. Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo- controlled trial. High Alt Med Biol. 2003;4:45-52.
23. Gertsch JH, Basnyat B, Johnson EW, Onopa J, Holck PS. Prevention of High Altitude Illness Trial Research Group. Randomised, double blind, placebo controlled comparison of gingko biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ. 2004;328: 797.
24. International Porter Protection Group. Available at: http:// www.ippg.net. Accessed July 20, 2008.